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ABSTRACT
Background: Composite outcomes that weight each component equally are commonly used to study treatment effects. 
We hypothesized that each component of a composite outcome would differentially affect patients’ overall health-
related quality of life (HRQL). 
Methods: We tested our hypothesis using data from 2 published clinical studies of treatment for heart failure, one 
comparing metformin and sulfonylurea and the other comparing digoxin and placebo. We applied the quality-adjust-
ed survival (QAS) approach, which incorporates HRQL data to accommodate differential weights for 2 components 
(in this analysis, death or admission to hospital) of a commonly used composite end point. For each of the 2 studies, 
the composite outcome was partitioned into its components, to which utility weights derived from the literature were 
assigned. Total QAS time determined for each treatment by the QAS analysis was compared with the results from 
traditional survival analyses based on Cox proportional hazards regression. 
Results: In the observational study of metformin in heart failure, the risk of the composite outcome of death or admis-
sion to hospital was lower for those receiving metformin therapy than for those who received sulfonylurea (event rate 
160 [77%] v. 658 [85%]; hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.70–0.99). With traditional survival 
analysis, the net gain was 0.82 years (95% CI 0.26–1.37), whereas the difference in QAS time was less, at 0.54 years 
(95% CI 0.20–0.89). In the randomized trial of digoxin therapy, the risk of the composite outcome was lower for those 
receiving the intervention than for those receiving placebo (event rate 1291 [38%] v. 1041 [31%]; HR 0.75, 95% CI 
0.69–0.82). With traditional survival analysis, the net gain was 0.06 years (95% CI 0.02–0.16), whereas the differ-
ence in QAS time was greater, at 0.11 years (95% CI 0.06–0.16). 
Interpretation: Studies that assume equal weights for the components of composite outcomes may overestimate or 
underestimate treatment effects. By incorporating HRQL into survival analyses, the impact of the various compo-
nents of the outcome can be assessed more directly.
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C
omposite  outcomes  are  common  in  clinical 
research,  especially  in  trials  of  cardiovascular 
disease.  The  potential  advantages  of  composite 
outcomes include higher event rates, better power and 
statistical efficiency, and integration of clinically import-
ant events into a single quantifiable outcome. However, 
several concerns have been raised, particularly regarding 
the interpretation of results when the components of the 
composite outcome affect patients’ health differentially 
or are associated with competing risks.1 For example, 
the composite outcome of death or admission to hospi-
tal is often used in studies of heart failure, but it could 
be difficult to compare the effects of 2 treatments if one 
treatment  reduces  mortality  but  increases  admissions 
and the other treatment has no effect on mortality but 
reduces admissions. 
One  concern  with  composite  outcomes  is  the  as-
sumption  that  each  component  of  the  outcome  (i.e., 
each health state) is equally important. Although this 
assumption is valid in certain cases, more often the in-
dividual components of a composite outcome will affect 
patients’ overall quality of life differently. One way to 
address this situation is to account for potential differ-
ences in health states by assigning differential weights 
to the components. In many instances where this has 
been attempted, the weights assigned have been based 
on  expert  opinion.2–5  However, the  appropriateness  of 
these expert-derived weights is controversial, which has 
probably contributed to the limited adoption of weighted 
methods.  Because  patients  ultimately  experience  the 
events in question, it seems reasonable to incorporate 
their perspectives when weighting composite outcomes 
in clinical research. 
One method for assigning weights that reflects the pa-
tient’s perspective is the use of health-related quality of 
life (HRQL). If HRQL is incorporated into survival analy-
ses, index measures (i.e., utilities) can be used to adjust 
for the unequal impact of health states used in composite 
outcomes, thereby providing a “weighted” survival out-
come that accounts for different degrees of quality and 
quantity of life.6 Furthermore, incorporation of HRQL 
into survival analysis would align clinical research with 
the  methods  of  economic  evaluations,  for  which  cost 
utility analyses (i.e., cost per quality-adjusted life year)7 
are recommended, thereby improving the assessment of 
health care interventions. This concept of using HRQL 
to adjust survival analyses for different health outcomes 
has been used in oncology,6 where it is referred to as 
quality-adjusted survival (QAS) analysis.8 To our know-
ledge, it has not been employed in cardiovascular disease 
or specifically for patients with heart failure. Here, we 
apply this method to the analysis of cardiovascular dis-
ease, using heart failure as our base example, since many 
studies  of  this  condition  evaluate  the  composite  out-
come of death or admission to hospital as the primary 
end point. Most patients and clinicians, however, would 
consider these disparate end points. Therefore, analyses 
of such composite outcomes may be improved with the 
QAS approach.  
Methods
Overview.  We  applied  the  QAS  technique  as  origin-
ally proposed by Cole and associates8 to the commonly 
reported composite outcome of death or admission to 
hospital using 2 previously published studies: an obser-
vational study of antidiabetic therapies in patients with 
diabetes and heart failure (the metformin study)9 and a 
randomized controlled trial comparing digoxin with pla-
cebo in patients with heart failure (the Digitalis Investi-
gation Group [DIG] study).10 A sample data set and SAS 
code have been provided with this article to illustrate the 
application of the QAS technique (see online Appendices 
A and B). Data for the DIG study were obtained from the 
National Heart, Lung, and Blood Institute, whereas the 
metformin study data were previously acquired by the 
investigators from Saskatchewan Health.
Data sources. The data sources and population for the 
study of metformin use in heart failure have been de-
scribed in detail elsewhere.9 Briefly, 1833 patients with 
diabetes newly treated with oral antidiabetic agents and 
incident heart failure were identified using the adminis-
trative databases of Saskatchewan Health. The patients 
were categorized into 3 mutually exclusive groups: 773 
(42%) were treated with sulfonylurea therapy alone, 208 
(11%) with metformin alone and 852 (47%) with combin-
ations of sulfonylurea and metformin. For the purposes 
of the current article, only patients who received either 
metformin or sulfonylurea monotherapy were included. 
All patients were followed prospectively until death, ter-
mination of Saskatchewan Health coverage or Decem-
ber 31, 1999. Maximum follow-up was 9 years.
With  standard  Cox  proportional  hazards  regres-
sion  techniques,  after  adjustment  for  potentially  con-
founding  variables  (i.e.,  age,  sex,  a  modified  chronic 
disease score,11,12 therapies known to affect heart failure 
outcomes  [angiotensin-converting  enzyme  inhibitors, 
angiotensin II blockers, b-blockers, antiplatelet agents, 
nitrates, lipid-lowering therapies, antiarrhythmic agents 
and  spironolactone]  and  total  physician  visits  before Open Medicine 2009;1(1):e42
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diagnosis of heart failure), there was a reduction in the 
hazard of events in favour of the metformin group com-
pared to sulfonylurea therapy for both all-cause mor-
tality (69 [33%] v. 404 [52%]; hazard ratio [HR] 0.70, 
95% confidence interval [CI] 0.54–0.91) and the com-
posite outcome of “all-cause mortality or all-cause hos-
pitalization” (160 [77%] v. 658 [85%]; HR 0.83, 95% CI 
0.70–0.99).9 
The rationale, design and results of the DIG study have 
been reported in detail elsewhere.10 A total of 6800 pa-
tients with heart failure and left ventricular ejection frac-
tion of 0.45% or less were randomly assigned to receive 
either digoxin or placebo. After an average follow-up of 
37 months, there was no difference between the study 
groups with respect to the primary outcome of all-cause 
mortality (1194 [35%] in the placebo group v. 1181 [35%] 
in the digoxin group; HR 0.99, 95% CI 0.91–1.07). There 
was a trend toward lower risk of death related to heart 
failure in the digoxin group than in the placebo group 
(394 [12%] v. 449 [13%]; HR 0.88, 95% CI 0.77–1.01). In 
addition, the risk for the composite outcome of death due 
to worsening heart failure or admission to hospital re-
lated to that diagnosis was lower in the digoxin group 
(1041 [31%] v. 1291 [38%]; HR 0.75, 95% CI 0.69–0.82).10
 
Weighted composite outcome. We applied the QAS 
analysis to the composite outcome of “all-cause mortal-
ity or all-cause hospitalization” in the metformin study 
and to the composite outcome of “heart failure-specific 
mortality or hospitalization” in the DIG study. In both 
of these case studies, we considered 3 successive stages 
through which a patient might transition: state H1, repre-
senting the patient’s initial health state before admission 
to hospital, death or censoring at the end of the study 
(i.e., the mean event-free survival time corresponding 
to the area under the composite outcome curve); state 
H2, representing the patient’s health state after a hospi-
tal stay until either death or censoring at the end of the 
study (i.e., area between the composite outcome survival 
curve and the mortality survival curve); and state H3, 
death (no time is associated with this health state). 
For the QAS analyses, each state was associated with 
a  specific  HRQL,  represented  by  a  utility  coefficient.8 
We  applied  validated  utility  coefficients  for  patients 
with heart failure taken from the literature, since HRQL 
measurements had not been collected in either of the 2 
case studies. For state H1, the utility coefficient was set 
at 0.81, based on Health Utilities Index Mark 3 (HUI3) 
scores observed for patients with heart disease and dia-
betes in the Canadian population.13 This value is similar 
to utility weights observed in patients with heart failure 
alone.14  Among  patients  with  heart  failure,  admission 
to hospital reduces HRQL by 30%,14 resulting in a util-
ity coefficient of 0.57 for state H2. By convention, the 
health state “dead” (H3) was assigned a utility score of 
0.13 For the traditional survival analysis, which assumes 
equal importance for each health state (i.e., H1 and H2), 
utility equal to 1 (i.e., perfect health) was used. We used 
the HUI3 utility scores in our analyses because this is 
the only utility measure of which we are aware that has 
specifically evaluated the effect of hospital admission on 
HRQL for patients with heart failure. We acknowledge, 
however, that it has not necessarily been applied to pa-
tients with heart failure and diabetes; therefore, we were 
limited to the estimate for patients with heart disease 
and diabetes in the Canadian population.
Analysis.  For  the  metformin  cohort  study,  the  tran-
sitional  survival  functions  for  each  health  state  (i.e., 
all-cause death or all-cause admission to hospital) for 
the 2 treatment groups were estimated using Cox pro-
portional hazards models (i.e., SAS code PHREG) with 
adjustments  for  the  confounding  covariates  and  the 
product-limit estimate of the baseline survival function.8 
The survival functions for the treatment groups were es-
timated using overall mean values for each covariate. 
In the DIG study, there were no significant differences 
in baseline characteristics between the patients in the 
digoxin and placebo groups because of the randomized 
study  design.10  Therefore,  we  estimated  the  survival 
functions using Cox proportional hazards models with-
out adjustments for covariates. We checked proportional 
hazards assumptions using log–log plots and time inter-
actions, with no violations noted for either study.
For  each  study,  we  first  estimated  the  Cox  propor-
tional hazards regression survival function (i.e., survival 
curves) for the health state “dead” (H3) as the event of 
interest in each treatment group. We then estimated the 
survival function for the composite outcome (death or 
admission to hospital) as the event of interest for each 
group. The mean time spent in each health state was cal-
culated by integrating the estimated survival function 
from 0 to the maximum limit of 7.8 years for the met-
formin study and 4.9 years for the DIG study. Time in 
state H1 (initial health state of the patient) was estimated 
as the integrated survival time for the composite outcome 
(death or admission to hospital). Time in state H2 (health 
state of the patient after a hospital stay) was calculated 
by integrating the overall survival time for death and 
subtracting the mean time spent in state H1. QAS time in Open Medicine 2010;1(1):e43
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each health state was then calculated by multiplying the 
mean time spent in each health state by the respective 
utility coefficient.8 Summation of these quality-adjusted 
times provided an estimate of the overall QAS time dur-
ing the study period for each treatment group. 
To generate estimates of the variability of the mean 
QAS time for the treatment groups, we used 500 boot-
strap samples for each study, with the 95% CI and corres-
ponding p values calculated according to the percentile 
method,15 whereby the QAS estimates spanning the 2.5 
and  97.5  percentiles  of  the  bootstrapped  distribution 
represented the 95% CI. 
Sensitivity analyses were performed to evaluate the 
effect of different utility coefficients for the health states 
on the results for both studies. The utility coefficients for 
health states H1 and H2 were increased or decreased by 
0.03, which is considered a clinically important differ-
ence on the HUI3.16 All analyses were conducted using 
SAS for Windows, version 9.1 (SAS Institute, Cary, N.C.).
Results
Metformin use in heart failure. In the metformin 
study, sulfonylurea users spent a mean of 1.21 years in 
health  state  H1  (survival  without  hospital  admission) 
and 2.89 years in health state H2 (after admission to hos-
pital until either death or censoring at the end of follow-
up) (Fig. 1A, Table 1). Conversely, metformin users spent 
a mean of 1.52 years in health state H1 and 3.40 years in 
health state H2 (Fig. 1B, Table 1). Using traditional sur-
vival analysis, which assumes that those who are alive 
are in perfect health (i.e., utility of 1 for health states 
H1 and H2) until the time of death, we determined that 
sulfonylurea users had a mean expected adjusted surviv-
al of 4.10 years, calculated as (1.21 years × utility of 1) + 
(2.89 years × utility of 1) and metformin users a mean 
expected adjusted survival of 4.92 years, calculated as 
(1.52 years × utility of 1) + (3.40 years × utility of 1). This 
translates into an average gain of 0.82 life-years (95% 
bootstrapped CI 0.26–1.37) associated with metformin 
use relative to sulfonylurea use. However, using the QAS 
approach, with an expected utility of 0.81 for health state 
H1 and 0.57 for health state H2, we determined that sul-
fonylurea users had a mean expected QAS time of 2.63 
years, calculated as (1.21 years × utility of 0.81) + (2.89 
years × utility of 0.57) (Fig. 1A, Table 1), and metformin 
users a mean expected QAS time of 3.17 years, calculat-
ed as (1.52 years × utility of 0.81) + (3.40 years × util-
ity of 0.57) (Fig. 1B, Table 1). Thus, metformin users had 
a  significant  net  increase  of  0.54  quality-adjusted  life 
years (QALYs) relative to those using sulfonylurea (95% 
bootstrapped  CI  0.20–0.89,  p  <  0.002).  In  this  case, 
traditional survival analysis led to a 34% overestima-
tion of potential benefits related to use of metformin in 
the treatment of patients with both diabetes and heart 
failure. 
DIG study. In the DIG study, placebo users spent a mean 
of 3.32 years in health state H1 (survival with no admis-
sion to hospital for heart failure) and 1.03 years in health 
state  H2  (after  admission  to  hospital  for  heart  failure 
until either death from heart failure or censoring at the 
end of follow-up) (Fig. 2A, Table 2). Conversely, digoxin 
users spent a mean 3.64 years in health state H1 and 0.77 
years in health state H2 (Fig. 2B, Table 2). Assuming per-
fect  health  before  death, 
as  in  traditional  survival 
analysis  (i.e.,  utility  of  1 
for all health states), pla-
cebo users had a mean ex-
pected  adjusted  survival 
of 4.35 years, calculated as 
(3.32 years × utility of 1) + 
(1.03 years × utility of 1), 
whereas digoxin users had 
a mean expected adjusted 
survival of 4.41 years, cal-
culated  as  (3.64  years  × 
utility of 1) + (0.77 years × 
utility of 1). This translates 
into a net survival benefit 
of  0.06  years  (95%  boot-
strapped CI 0.00–0.12) for 
Table 2: Integrated survival time for placebo and digoxin groups according to health state
Survival, years (95% CI)*
Group In health state H1 In health state H2 Total Quality-adjusted
Placebo 3.32 (3.25–3.39) 1.03 (0.98–1.09) 4.35 (4.31–4.39) 3.28 (3.24–3.31)
Digoxin 3.64 (3.56–3.70) 0.77 (0.72–0.83) 4.41 (4.37–4.45) 3.39 (3.35–3.42)
CI = confidence interval, H1 = patient’s initial health state before admission to hospital, death or censoring at the end of the study, 
H2 = patient’s health state after a hospital admission until either death or censoring at the end of the study.
*95% CI values generated from the bootstrap procedure (500 samples).
Table 1: Integrated survival time for sulfonylurea and metformin groups according to health state
Survival, years (95% CI)*
Group In health state H1 In health state H2 Total Quality-adjusted
Sulfonylurea 1.21 (1.06–1.32) 2.89 (2.65–3.17) 4.10 (3.82–4.41) 2.63 (2.45–2.82)
Metformin 1.52 (1.27–1.82) 3.40 (2.81–3.92) 4.92 (4.35–5.41) 3.17 (2.81–3.48)
CI = confidence interval, H1 = patient’s initial health state before admission to hospital, death or censoring at the end of the study, 
H2 = patient’s health state after a hospital admission until either death or censoring at the end of the study.
*95% CI values generated from the bootstrap procedure (500 samples).Open Medicine 2010;1(1):e44
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digoxin users relative to placebo users. However, accord-
ing to the QAS approach, placebo users had an mean ex-
pected QAS time of 3.28 years, calculated as (3.32 years × 
utility of 0.81) + (1.03 years × utility of 0.57), whereas the 
digoxin  users  had  a  mean  ex-
pected QAS time of 3.39 years, 
calculated  as  (3.64  years  × 
utility  of  0.81)  +  (0.77  years  × 
utility  of  0.57).  Therefore,  after 
taking  into  account  the  greater 
time spent before first admission   
for  heart  failure,  the  digoxin 
group  had  a  net  gain  of  0.11 
QALYs  over  the  placebo  group 
(95% bootstrapped CI 0.06–0.16, 
p < 0.001).  Furthermore,  this 
estimate is 83% higher than the 
standard survival estimate based 
on  equally  weighted  outcomes. 
In this case, traditional analytic 
methods led to an underestima-
tion of the potential benefits relat-
ed to using digoxin for treatment 
of patients with heart failure.
Sensitivity  analyses.  In  the 
base-case  analyses  described 
above,  we  applied  deterministic 
utility coefficients to health states 
taken from the literature. We also 
conducted  a  sensitivity  analysis 
to assess the effect of varying the 
utility coefficients by a clinically 
important amount (0.03) on the 
QALY  estimates  for  health  state 
H1  and  H2  for  the  metformin 
and  DIG  studies.  Variations  in 
the  utility  coefficients  resulted 
in changes to both the individ-
ual  QALYs  calculated  for  each 
health state and the differences 
between study groups. All sensi-
tivity  analyses  confirmed  that 
the standard survival estimates 
overestimated  the  benefits  of 
metformin by 30% to 35% in the 
observational  metformin  study 
and  underestimated  benefits  of 
digoxin  by  50%  to  117%  in  the 
DIG study (see online Appendix 
C for a full report of the sensitivity results). Additional an-
alyses in which the HUI3 utilities were varied by an excep-
tionally large clinical change of 0.1 (i.e., change expected if 
a person with diabetes were to be cured of heart disease)13 
Figure 1: Partitioned survival functions for all-cause mortality and all-cause admission  
to hospital in an observational study of antidiabetic agents in patients with heart  
failure. T1 = �i�� s���� i� h�a��h s�a�� 1. T2 = Ti�� s���� i� h�a��h s�a�� 2. Dash�� ��� 
�i�� = a����a�s� ����a�i��. S��i� ���� �i�� = a����a�s� h�s�i�a� a��issi�� �� ����a�i��.   
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consistently  showed  that  traditional  survival  analyses 
overestimated treatment effects in the metformin study. 
Similarly,  traditional  survival  analyses  underestimated 
treatment effects in the digoxin study, with the exception 
of the analysis in which the HUI3 utility was decreased 
by 0.1 for health state H1 and increased by 0.1 for health 
state H2. 
Interpretation
Using heart failure as an example, 
we have applied and demonstrated 
a method that adjusts survival to 
deal with the potentially unequal 
impact of the individual compon-
ents of composite outcomes. If an 
estimate of the impact on patients’ 
HRQL is incorporated into surviv-
al analyses, a weighted composite 
outcome may provide a represen-
tation  of  the  benefits  (or  harms) 
associated  with  a  therapy  that  is 
more  pertinent  to  the  individual 
patient. In the 2 case studies exam-
ined here, incorporation of HRQL 
into the survival analyses resulted 
in  quality-adjusted  survival  esti-
mates that ranged from 34% lower 
to 83% higher than those derived 
from traditional survival analyses 
using  equally  weighted  compon-
ents for the composite outcomes. 
Composite  outcomes  are  com-
monly  reported,  but  the  tacit  as-
sumption that each component is of 
equal importance to patients, pro-
viders and payers seems untenable 
and is rarely met. Increasing evi-
dence  suggests  that  components 
of a composite end point that have 
the greatest effect on patients, such 
as death, contribute little to the es-
timates of composite end points in 
cardiovascular-related  research, 
whereas  those  components  with 
the  least  impact  on  patients  con-
tribute the most.17 Not surprisingly, 
the results of previous studies have 
suggested  that  the  use  of  equally 
weighted components in composite 
end points may lead to biased con-
clusions  and  to  overestimates  of 
treatment effects in cardiovascular-related trials.5 Our 
results also illustrate that bias may occur, but in either 
direction. 
As a result, researchers evaluating the merits of stud-
ies employing composite end points should be cautious of 
the influence of the individual components of such com-
posite end points. It is clear that additional techniques, 
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Figure 2: Partitioned survival functions for death due to worsening heart failure or 
admission to hospital related to that diagnosis in a randomized trial of digoxin. 
T1 = �i�� s���� i� h�a��h s�a�� 1. T2 = Ti�� s���� i� h�a��h s�a�� 2. Dash�� ��� �i�� = 
����a�i�� ���a��� �� h�a�� �ai����. S��i� ���� �i�� = h�a����ai��������a��� h�s�i�a�  
a��issi�� �� ����a�i��.
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like QAS, could improve the clinical interpretability of 
composite end points. Notably, the QAS approach does 
not influence either the estimated hazard ratios or the 
survival  curves  often  reported  in  cardiovascular  re-
search; rather, it represents complementary information 
that allows for adjustment of the survival time, thereby 
“weighting” the survival outcome by incorporating dif-
ferent  degrees  of  quality  and  quantity  of  life.  Clearly, 
alternative analytical methods such as competing risk 
models or multistage models can also be employed to 
address  the  issue  of  multiple  end  points  and  compet-
ing events observed in composite outcomes. However, 
in contrast to the QAS approach, both of these methods 
weight  each  component  equally,  and  neither  places  a 
“value” on the relative survival time gained or lost in as-
sociation with the competing events. 
Our primary intention in undertaking this study was 
to examine differences in the magnitude of the QAS es-
timates between the treatment groups (e.g., digoxin and 
placebo in the DIG study) and to determine how differ-
ential  weighting  of  composite  outcomes  might  change 
the interpretation of the data. The QAS approach gen-
erates  survival  time  associated  with  “perfect  health” 
rather than the overall survival generated by the trad-
itional unweighted approach. For example, in the DIG 
trial, the risk of hospital admission or death due to heart 
failure  was  reported  to  be  significantly  lower  in  the 
digoxin group (HR 0.75, 95% CI 0.69–0.82).10 However, 
the analysis that we have outlined above quantifies this 
benefit as a gain of only 0.06 life-years with the trad-
itional unweighted approach and only 0.11 QALYs with 
the weighted QAS approach. This difference is of per-
haps questionable clinical significance for the DIG study, 
but such may not always be the case. Conversely, the 
gain of 0.54 QALYs observed with metformin therapy is 
similar to that observed with the use of other proven ef-
ficacious therapies (relative to placebo) in patients with 
heart failure.18 Furthermore, the difference in the QAS 
estimates for the unweighted and weighted approaches 
for metformin therapy (0.82 v. 0.54) would be similar to 
the HRQL effects of choosing not to prescribe angiotens-
in-converting enzyme inhibitors for patients with heart 
failure.18 In these 2 examples, both therapies remained 
beneficial after adjustment for HRQL, but one could eas-
ily foresee clinical trials in which marginal benefits de-
termined  with  unweighted  composite  outcomes  might 
be  nonsignificant  if  the  weighted  approach  were  used 
or vice versa. In addition, unlike most traditional sur-
vival analyses evaluating composite outcomes, the QAS 
approach is directly amenable to economic evaluations 
(e.g., cost utility analysis incorporating QALYs). Thus, we 
believe that better-informed treatment decisions may re-
sult from incorporating measures of clinical impact into 
summary effect estimates. 
Importantly,  appropriate  selection  of  the  utility 
weights is required, as shown by the modest effect on 
the QAS estimates in our sensitivity analyses. Prospect-
ive collection of utilities in the setting of randomized 
controlled trials or cohort studies would permit incor-
poration of study-specific utilities into the QAS method. 
For example, collection of utility estimates at baseline, 
at the time of clinically important events and at regu-
larly scheduled time points (e.g., every 6 months) might 
allow  more  complete  evaluation  of  the  effect  of  ther-
apies  on  HRQL  in  clinical  trials.  Furthermore,  since 
the periods of evaluation are consecutive, these time-
specific health states could be easily incorporated into 
the QAS approach. In studies where prospective collec-
tion of utility estimates is not possible, carefully selected 
literature-based  estimates  (i.e.,  utility  estimates  from 
patient populations that are similar in terms of socio-
demographic characteristics [age, sex, ethnicity], sever-
ity of disease, location of care [hospital, community] and 
health care systems) or threshold utility analyses for un-
known utility estimates6,8 may be used, but they should 
be justified and subject to sensitivity analyses such as we 
have illustrated. 
Although there are several advantages to using QAS 
analyses, there are also some limitations. First, the qual-
ity-adjusted  survival  estimate  that  we  have  described 
must be restricted to a set time limit. Thus, in our analy-
ses, the integration range was limited to the maximum 
follow-up of 7.8 years for the metformin study and 4.9 
years for the DIG study, identical with that used in the 
traditional survival analysis. As such, this method can-
not provide “lifetime” estimates associated with the ther-
apy itself, but could be incorporated into projected life 
expectancy models to provide such estimates. Second, 
we used the simplest presentation of this method, which 
assumes a progressive health state model where admis-
sion to hospital precedes death. Although this is appro-
priate for many disease conditions and most composite 
outcomes, it may not be suitable for all; consider, for ex-
ample, a composite outcome of admission to hospital or 
coronary  artery  bypass  grafting.  Parametric  methods 
have been developed to overcome these limitations.19 In 
addition, these models may be extended to account for 
repeated failure times and the use of time-varying co-
variates.8 Third, all limitations and assumptions associ-
ated with Cox proportional hazards regression also apply Open Medicine 2010;1(1):e47
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costs  associated  with  therapy  may  be  more  precisely 
quantified and may be made transparent for patients, 
providers and policy-makers.
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